Pfizer Shares Surge on Strong Earnings and Raised 2025 Outlook
Pfizer's stock closed up over 5% following a robust Q2 earnings report that surpassed analyst expectations. Adjusted diluted EPS reached $0.78 against a $0.58 consensus, while revenue hit $14.7 billion—$1 billion above estimates. The pharma giant reaffirmed its 2025 revenue guidance of $61B-$64B and raised EPS projections by $0.10 to $3.00 midpoint.
Despite a 17% annual decline and 32% five-year slump post-COVID vaccine windfall, CEO Albert Bourla emphasized upcoming pipeline catalysts: "Our clinical readouts will demonstrate a clear growth trajectory through 2030." The rally comes amid sector-wide pressure as political focus intensifies on drug pricing reforms.